HB3326 would require all Commuter Rail Board trains, which includes Metra service, to carry naloxone or another opioid antagonist while in operation. The medication would have to be stored in easily accessible locations throughout the train cars so it can be reached quickly in an emergency. The bill limits administration to train conductors or other individuals who are trained in the use and administration of opioid antagonists, and it directs the Commuter Rail Board to adopt rules to carry out the requirement.
The bill also amends the Good Samaritan Act to provide civil liability protection for a conductor or other trained individual who, in good faith, dispenses or administers an opioid antagonist under the new rail requirement. That protection would not apply in cases of willful or wanton misconduct. The bill is effective January 1, 2027, and would add new provisions to both the Regional Transportation Authority Act and the Good Samaritan Act.
Impact
HB3326 would create a new operational safety requirement for commuter rail service in Illinois by mandating naloxone or a similar opioid antagonist on all Commuter Rail Board trains. It would also add a specific liability shield for trained rail personnel who administer the medication in good faith, thereby modifying the Good Samaritan Act to cover this rail-based emergency response. The practical effect would be to impose training, storage, and rulemaking obligations on the Commuter Rail Board and to expand access to overdose-reversal medication in transit settings.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a public-safety and overdose-response bill, with an emphasis on preparedness and emergency intervention on commuter trains. No committee transcript or vote record is available, so there is no documented opposition or support in the provided materials. The caption, "METRA-NALOXONE REQUIREMENT," suggests the proposal is straightforward and targeted rather than broadly controversial.
Contention
The main policy questions raised by the bill are operational and liability-related. One point of contention could be whether requiring naloxone on every commuter rail train creates added training, storage, and implementation burdens for the Commuter Rail Board and its personnel. Another possible issue is the scope of the civil immunity provision: the bill protects trained conductors and others acting in good faith, but only up to the standard exception for willful or wanton misconduct. No specific opposing arguments, amendments, or recorded debate are included in the provided materials.